本文選題：環(huán)核苷酸磷酸二酯酶4B2 + 重組表達(dá)　； 參考：《重慶醫(yī)科大學(xué)》2017年碩士論文

【摘要】：人磷酸二酯酶同工酶4(phosphodiesterase,PDE4)選擇性水解cAMP,并分為PDE4A、4B、4C、4D四種亞型。參與炎癥反應(yīng)的單核細(xì)胞和中性粒細(xì)胞以表達(dá)PDE4B2為主。因此,相應(yīng)的PDE4抑制劑可用于治療哮喘、慢性阻塞性肺病等炎癥相關(guān)疾病。磁珠固定化靶蛋白可快速篩選潛在抑制劑混合物,但需要低成本大量表達(dá)高活性靶蛋白。前期研究發(fā)現(xiàn),PDE4B2在原核細(xì)胞可溶表達(dá)豐度低且純化過(guò)程不穩(wěn)定。有報(bào)道顯示,現(xiàn)有PDE4B2抑制劑的毒副作用與人全長(zhǎng)PDE4B2以咯利普蘭(R-rolipram)表征的高親和力結(jié)合構(gòu)象相關(guān),而治療作用與以R-rolipram表征的活性位點(diǎn)低親和力結(jié)合構(gòu)象相關(guān)。因此,本論文通過(guò)不同融合表達(dá)方式對(duì)PDE4B2全長(zhǎng)及152-528aa截短突變體進(jìn)行克隆表達(dá)純化及表征,以期獲得大量可溶表達(dá)的高表觀比活且處于以R-rolipram表征的低親和力結(jié)合狀態(tài)的PDE4B2融合蛋白。將人磷酸二酯酶4B2(hPDE4B2)全長(zhǎng)和152-528aa截短突變體融合6His-SUMO在大腸桿菌重組表達(dá),經(jīng)Ni2+-NTA純化獲得hPDE4B2全長(zhǎng)SF-h PDE4B2和截短突變體ST-hPDE4B2重組蛋白。用Western blot檢測(cè)多肽成分;用偶聯(lián)堿性磷酸酶的孔雀綠定磷法測(cè)定酶活性,表征其km和對(duì)模型化合物的抑制常數(shù)。結(jié)果顯示,純化后的st-hpde4b2純度較sf-hpde4b2高,st-hpde4b2(0.03u·mg-1)表觀比活性接近sf-hpde4b2(1.31u·mg-1)的40倍,活性收率超過(guò)100倍;此表達(dá)純化方案總活性收率不高,且westernblot顯示均有較多降解片段;測(cè)定(r)-rolipram和罌粟堿的抑制常數(shù)表明,sf-hpde4b2對(duì)(r)-rolipram主要為高親和力結(jié)合構(gòu)象,而st-hpde4b2主要為低親和力結(jié)合構(gòu)象。對(duì)代表化合物的抑制常數(shù)進(jìn)行數(shù)學(xué)分析,發(fā)現(xiàn)其雙對(duì)數(shù)模型具有單調(diào)相關(guān)性。因此,與sf-hpde4b2相比,st-hpde4b2用于初步篩選抗炎活性hpde4b2抑制劑可能更有優(yōu)勢(shì)。用同源重組的方法將hpde4b2全長(zhǎng)和152-528aa截短突變體基因克隆到帶有g(shù)st標(biāo)簽的載體pgex-6p-1上,表達(dá)后經(jīng)gst親和層析柱純化分別獲得n-端融合gst的人全長(zhǎng)hpde4b2(gf-hpde4b2)和截短突變體(gt-hpde4b2)。然而,純化后的gf-hpde4b2最大表觀比活為0.01u·mg-1,gf-hpde4b2最大表觀比活為0.05u·mg-1。gf-hpde4b2和gt-hpde4b2酶活性收率均較低。進(jìn)一步探索雙標(biāo)簽純化方法,將hpde4b2的n-端和c端與mbp和6-his標(biāo)簽三種形式融合:n-mbp/6his-c、n-6his/mbp-c和n-6his-mbp/6his-c,分別獲得mcf-hpde4b2/mct-hpde4b2(帶n-mbp/6his-c)、mnf-hpde4b2/mnt-hpde4b2(帶n-6his/mbp-c)、mf-hpde4b2/mt-hpde4b2(帶n-6his-mbp/6his-c)六種融合蛋白基因質(zhì)粒,表達(dá)后經(jīng)ni2+-nta和mbp親和層析純化獲得的全長(zhǎng)hpde4b2表觀比活性依次是:mcf-hpde4b2(1.11u·mg-1)mf-hpde4b2(0.1U·mg-1)MNF-hPDE4B2(0.01 U·mg-1);截短突變體表觀比活性依次是:MCT-hPDE4B2(1.25 U·mg-1)MNF-hPDE4B2(0.6 U·mg-1)MF-hPDE4B2(0.3 U·mg-1);全長(zhǎng)hPDE4B2和截短突變體重組蛋白的活性收率也顯著高于前兩種方案。鑒于測(cè)定PDE4活性篩選抑制劑對(duì)靶蛋白活性的要求,以MCF-h PDE4B2和MCT-hPDE4B2為靶蛋白在成本上顯得更有優(yōu)勢(shì)。綜上所述,本研究成功獲得hPDE4B2全長(zhǎng)和截短突變體與三種不同標(biāo)簽的融合表達(dá)重組蛋白:融合6His-SUMO標(biāo)簽的hPDE4B2截短突變體的活性收率效果較hPDE4B2全長(zhǎng)好;融合GST標(biāo)簽活性收率效果均不理想;N端融合MBP標(biāo)簽C端融合6his標(biāo)簽的hPDE4B2全長(zhǎng)和截短突變體融合表達(dá)及純化方案的活性收率最好。因此,推薦高通量初篩潛在抗炎活性的PDE4抑制劑用MCT-hPDE4B2,確認(rèn)潛在抗炎活性的PDE4抑制劑用MCF-hPDE4B2。
[Abstract]:The human phosphodiesterase isoenzyme 4 (phosphodiesterase, PDE4) selectively hydrolyzed cAMP and divided into four subtypes of PDE4A, 4B, 4C, 4D. The monocytes and neutrophils involved in the inflammatory response expressed PDE4B2. Therefore, the corresponding PDE4 inhibitors can be used in the treatment of asthma, chronic obstructive pulmonary disease and other inflammatory related diseases. Magnetic beads immobilized target protein The potential inhibitor mixture can be quickly screened, but high activity target proteins are needed at low cost. Previous studies have found that PDE4B2 has low soluble expression in prokaryotic cells and is unstable in purification process. It is reported that the toxic side effects of existing PDE4B2 inhibitors are associated with the high affinity of human full-length PDE4B2 with the high affinity of R-rolipram. Conformation is related, and the therapeutic effect is related to the conformation of low affinity binding to the active site characterized by R-rolipram. Therefore, the whole length of PDE4B2 and the truncated 152-528aa mutants were cloned and characterized by different fusion expressions, in order to obtain a large amount of soluble expressed high apparent specific activity and be characterized by R-rolipram. PDE4B2 fusion protein of low affinity binding state. Recombinant human phosphodiesterase 4B2 (hPDE4B2) full length and 152-528aa truncated mutants were fused 6His-SUMO in Escherichia coli, hPDE4B2 full SF-h PDE4B2 and truncated mutant ST-hPDE4B2 recombinant protein was purified by Ni2+-NTA. The polypeptide components were detected by Western blot. The enzyme activity of malachite green and phosphorus was determined to characterize its km and the inhibition constant to the model compound. The results showed that the purity of purified st-hpde4b2 was higher than that of sf-hpde4b2, and the apparent specific activity of st-hpde4b2 (0.03u. Mg-1) was 40 times that of sf-hpde4b2 (1.31u. Mg-1), and the yield was over 100 times, and the total yield of the expression and purification scheme was not high, and Wester was not high, and Wester was not high. Nblot showed that there were more degradation fragments, and the inhibition constants of (R) -rolipram and papaverine showed that sf-hpde4b2 to (R) -rolipram was mainly a high affinity binding conformation, while st-hpde4b2 was mainly a low affinity binding conformation. The mathematical analysis of the inhibition constants for the representative compounds showed that the double logarithmic model had a monotone correlation. Therefore, Compared with sf-hpde4b2, st-hpde4b2 may be more advantageous for the preliminary screening of anti inflammatory hpde4b2 inhibitors. The whole length of hpde4b2 and the 152-528aa truncated mutant gene were cloned to the carrier pgex-6p-1 with the GST label using the homologous recombination method, and the whole length hpde4b2 (gf-) of the n- terminal fusion GST after the expression of the GST affinity chromatography column was expressed after the expression of the GST affinity chromatography column. Hpde4b2) and truncated mutants (gt-hpde4b2). However, the maximum apparent ratio of the purified gf-hpde4b2 is 0.01u. Mg-1, and the maximum apparent ratio of gf-hpde4b2 to the activity of 0.05u. Mg-1.gf-hpde4b2 and gt-hpde4b2 enzyme is lower. Further explore the double label purification method, which combines the n- and C ends of hpde4b2 with the three forms: 6his-c, n-6his/mbp-c and n-6his-mbp/6his-c, respectively obtained mcf-hpde4b2/mct-hpde4b2 (n-mbp/6his-c), mnf-hpde4b2/mnt-hpde4b2 (n-6his/mbp-c), mf-hpde4b2/mt-hpde4b2 (n-6his-mbp/6his-c) six fusion protein gene plasmids, after expression by ni2+-nta and MBP affinity chromatography, the full length hpde4b2 apparent specific activity is in turn: Mcf-hpde4b2 (1.11u. Mg-1) mf-hpde4b2 (0.1U. Mg-1) MNF-hPDE4B2 (0.01 U. Mg-1); the apparent specific activity of the truncated body is as follows: MCT-hPDE4B2 (1.25 U mg-1). The yield of egg white in the whole length and the truncated body weight group is significantly higher than the first two schemes. The requirements for the activity of target proteins by selective inhibitors, MCF-h PDE4B2 and MCT-hPDE4B2 as target proteins are more advantageous in cost. To sum up, this study successfully obtained the fusion expression of hPDE4B2 full length and truncated mutants and three different labels: the activity yield of hPDE4B2 truncated mutant with 6His-SUMO tag is more effective than hPD The full length of E4B2 is good; the effect of the fusion GST tag active yield is not ideal; the activity yield of the hPDE4B2 full length and the truncated mutant of the N terminal fusion MBP tag C terminal fusion 6His tag is the best. Therefore, the PDE4 inhibitor which recommends the potential anti-inflammatory activity of the high throughput screening is used to confirm the PDE4 inhibitor for the potential anti-inflammatory activity. Using MCF-hPDE4B2.
【學(xué)位授予單位】：重慶醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R3411

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 孫奮勇,陳小佳,朱偉杰,謝秋玲,吳健虹,徐萬(wàn)祥,洪岸,李菁;豬卵透明帶-3β截短型蛋白在原核系統(tǒng)中的表達(dá)研究[J];生殖與避孕;2005年06期

2 李瑩,鄧?guó)櫂I(yè),狄春輝,施群,韓文玲,馬大龍;重組人截短型胰島素樣生長(zhǎng)因子1在大腸桿菌中的高效表達(dá)[J];中國(guó)免疫學(xué)雜志;2000年02期

3 馬開利;苑玉和;胡金鳳;孫建棟;劉巖;李博宇;陳乃宏;;α-synuclein C端截短體的胞內(nèi)分布[J];中國(guó)藥理學(xué)通報(bào);2010年01期

4 蘧艷峰;李卓玉;郭晨云;郭素堂;史天良;袁靜明;;截短型細(xì)胞毒素Gelonin的分子構(gòu)象和生物活性[J];中國(guó)生物化學(xué)與分子生物學(xué)報(bào);2006年05期

5 鄧林;劉孝菊;龔守良;王會(huì)巖;田海山;王曉杰;馬吉?jiǎng)?李校X;;重組截短型人角質(zhì)細(xì)胞生長(zhǎng)因子-1的表達(dá)及純化[J];吉林大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2010年04期

6 邸雅南;胡大榮;胡學(xué)玲;吳憶貧;;HBVC基因截短型突變體抗HBV作用研究[J];中華傳染病雜志;2005年05期

7 張濤,彭祥兵,端義坤,余模松;HIV-2跨膜蛋白gp36的截短及表達(dá)[J];中國(guó)生物制品學(xué)雜志;2003年03期

8 李靜舒;李玉英;崔曉東;王轉(zhuǎn)花;;截短型rBTI的表達(dá)、純化及其對(duì)EC9706細(xì)胞生長(zhǎng)的抑制作用[J];中國(guó)生物化學(xué)與分子生物學(xué)報(bào);2011年05期

9 薛萍;朱小靜;劉孝菊;李一蘭;南佳;姜潮;李校X;;重組截短型人角質(zhì)細(xì)胞生長(zhǎng)因子1在昆蟲細(xì)胞中的表達(dá)[J];吉林大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2012年04期

10 藺宇;劉少君;;SCIRR 10截短體真核表達(dá)載體的構(gòu)建及其在COS-7細(xì)胞中的表達(dá)[J];吉林大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2011年02期

相關(guān)會(huì)議論文 前7條

1 陳鐵鳳;;俄語(yǔ)口語(yǔ)截短復(fù)合詞研究[A];中國(guó)首屆“海峽兩岸俄語(yǔ)教學(xué)與研究學(xué)術(shù)討論會(huì)”論文摘要集[C];2005年

2 陳鐵鳳;;俄語(yǔ)口語(yǔ)截短復(fù)合詞研究[A];中國(guó)首屆“海峽兩岸俄語(yǔ)教學(xué)與研究學(xué)術(shù)討論會(huì)”論文集[C];2005年

3 李靜舒;王轉(zhuǎn)花;;截短型rBTI的表達(dá)、純化及性質(zhì)研究[A];泛環(huán)渤海地區(qū)九省市生物化學(xué)與分子生物學(xué)會(huì)——2011年學(xué)術(shù)交流會(huì)論文集[C];2011年

4 姜成剛;高旭;馬建;林躍智;趙立平;呂曉玲;周建華;;跨膜蛋白截短突變對(duì)馬傳染性貧血弱毒疫苗株體內(nèi)復(fù)制特性和免疫誘導(dǎo)能力的影響[A];中國(guó)畜牧獸醫(yī)學(xué)會(huì)畜牧獸醫(yī)生物技術(shù)學(xué)分會(huì)暨中國(guó)免疫學(xué)會(huì)獸醫(yī)免疫分會(huì)第八次學(xué)術(shù)研討會(huì)論文集[C];2010年

5 聞曉波;冉旭華;魏曉曼;崔玉東;;Gottfried和SB-1A株豬輪狀病毒截短VP8*蛋白的免疫原性分析[A];中國(guó)畜牧獸醫(yī)學(xué)會(huì)家畜傳染病學(xué)分會(huì)第八屆全國(guó)會(huì)員代表大會(huì)暨第十五次學(xué)術(shù)研討會(huì)論文集[C];2013年

6 王志宇;王健偉;何深一;吳圍屏;韓金祥;洪濤;;截短型A組輪狀病毒VP6在E.coli中的高效表達(dá)[A];山東省藥學(xué)會(huì)2006年生化與生物技術(shù)藥物學(xué)術(shù)研討會(huì)論文集[C];2006年

7 李�；�;鄭世軍;;松鼠葡萄球菌脫皮毒素C活性功能域的分析[A];中國(guó)畜牧獸醫(yī)學(xué)會(huì)動(dòng)物傳染病學(xué)分會(huì)第四次豬病防控學(xué)術(shù)研討會(huì)論文集[C];2010年

相關(guān)博士學(xué)位論文 前1條

1 施少華;表達(dá)截短N(yùn)S1和嵌合HA新型H5N1亞型禽流感疫苗的研制[D];揚(yáng)州大學(xué);2016年

相關(guān)碩士學(xué)位論文 前10條

1 趙影;山羊溶酶體α-甘露糖苷酶D221位點(diǎn)的截短表達(dá)及其特性研究[D];西北農(nóng)林科技大學(xué);2016年

2 張景盼;酸性α-淀粉酶基因的截短突變及性質(zhì)研究[D];河南農(nóng)業(yè)大學(xué);2013年

3 張祥;不同融合方式表達(dá)人全長(zhǎng)PDE4B2及其截短突變體的比較[D];重慶醫(yī)科大學(xué);2017年

4 李華;完整型及截短型人胰島素樣生長(zhǎng)因子Ⅰ基因的克隆及其表達(dá)[D];天津醫(yī)科大學(xué);2002年

5 陳琴;Midkine新亞型和相應(yīng)RNA新剪切形式的發(fā)現(xiàn)[D];廈門大學(xué);2006年

6 曾敏怡;SCN1A基因截短突變患者的臨床分析及截短突變誘導(dǎo)的NMD機(jī)制研究[D];廣州醫(yī)科大學(xué);2014年

7 李靜舒;截短型rBTI的表達(dá)、純化及性質(zhì)研究[D];山西大學(xué);2011年

8 李偉;IBRV截短gB基因的表達(dá)及ELISA診斷方法的建立[D];吉林大學(xué);2009年

9 吳健虹;截短型EGFR在COS7與CHO-K1細(xì)胞的表達(dá)研究[D];暨南大學(xué);2006年

10 胡薇;巰基氧化酶及其相關(guān)探針研究[D];華東理工大學(xué);2011年

，

本文編號(hào)：1901455